BMJ  2007;335:541 (15 September), doi:10.1136/bmj.39336.444282.59

Observations

Response

Alzheimer's Society replies to Iain Chalmers

The first 150 words of the full text of this article appear below.

The question of who should have access to Alzheimer's drugs has sparked a heated debate on the way the National Institute for Health and Clinical Excellence (NICE) decides whether treatments are cost effective. Sir Iain Chalmers attacked the Alzheimer's Society (BMJ 2007;335:400 doi: 10.1136/bmj.39309.704016.BD) for our legal challenge against the NICE guidance on Alzheimer's drugs. He alleges that we formed an alliance with pharmaceutical companies to the detriment of people affected by dementia and challenges us to be transparent about our commercial relationships.

I wonder why supposedly informed commentators cannot conceive that our actions might be genuinely informed by the views of our members. Earlier this year, I met with NICE chairman Sir Michael Rawlins to challenge his apparent view that commercial interests were driving the campaigning agenda of the society. Now another associate of NICE repeats these tired allegations. We are an independent organisation. Funding is a . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

The Alzheimer's Society, drug manufacturers, and public trust

Iain Chalmers
BMJ 2007 335: 400. [Extract] [Full Text] [PDF]

Rapid Responses:

Read all Rapid Responses

The Alzheimer's Society and public trust

Iain Chalmers
bmj.com, 20 Sep 2007 [Full text]

Why I am no longer a member of the Alzheimer Society

Linda Furlini
bmj.com, 26 Sep 2007 [Full text]

Alzheimer Society of Canada responds to Linda Furlini ‘Why I am no longer a member of the Alzheimer Society’

Scott Dudgeon
bmj.com, 3 Oct 2007 [Full text]

Online poll

Find out more >>